Adenocarcinoma antigenic determinants, methods for their production and use, and broadly-specific human monoclonal antibodies reactive to the epitopes. These epitopes, which can be physically recapitulated, are conserved across a range of adenocarcinomas and are capable of eliciting an immune response in humans.

The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses.

An improved stabilization buffer for use in the lyophilization of Neospora and other protozoans is disclosed. Also disclosed is an improved lyophilization method, which includes controlling ice nucleation during the freezing step.

The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.

The present invention relates to photon-irradiated streptococcal vaccine preparations and methods for their use.

The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.

The present invention discloses novel isolates of Neorickettsia risticii, compositions comprising such isolates, vaccines and methods for using such vaccines against Potomac Horse Fever.

The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The invention also provides methods of rendering bacteria in culture resistant to ionizing radiation (IR), with these methods comprising culturing the bacteria in the presence of a radiation-protective composition.

Provided is a protein having Toxoplasma immunogenicity, the protein being a cyclophilin mutant protein and consisting of the amino acid sequence as shown in SED 2. Further provided is a nucleic acid that may encode a protein having Toxoplasma immunogenicity, which has the nucleic acid sequence as shown in SEQ ID NO. 1. Further provided is a vaccine, which is obtained by double-digesting a Toxoplasma antigen gene and then linking the same to a prokaryotic expression vector such as pET28a, and transforming the same into a prokaryotic expression engineering strain such as BL21(DE3), thereby inducing the high-efficiency expression thereof, wherein the inducing the high-efficiency expression thereof, wherein the purified protein is a soluble protein which maintains specific immunogenicity thereof.

The present invention provides methods of treating or preventing gestational diabetes by administering Lactobacillus rhamnosus HN001 or derivatives thereof, in addition to uses, compositions, and medicaments comprising Lactobacillus rhamnosus HN001 or derivatives thereof to treat or prevent gestational diabetes mellitus.